{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:30:37Z","timestamp":1791304237107,"version":"4.3.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.04.021","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T21:36:42Z","timestamp":1650404202000},"page":"3009-3017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines"],"prefix":"10.1016","volume":"40","author":[{"given":"Danielle","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan W.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Beaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Warfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.vaccine.2022.04.021_b0005","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJMra1406035","article-title":"Chikungunya virus and the global spread of a mosquito-borne disease","volume":"372","author":"Weaver","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.021_b0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41584-019-0276-9","article-title":"Rheumatic manifestations of chikungunya: emerging concepts and interventions","volume":"15","author":"Suhrbier","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.021_b0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrmicro2368","article-title":"Biology and pathogenesis of chikungunya virus","volume":"8","author":"Schwartz","year":"2010","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.021_b0020","doi-asserted-by":"crossref","first-page":"882","DOI":"10.4269\/ajtmh.13-0403","article-title":"Incubation periods of mosquito-borne viral infections: a systematic review","volume":"90","author":"Rudolph","year":"2014","journal-title":"Am J Trop Med Hyg"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.021_b0025","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/trstmh\/try063","article-title":"Chikungunya chronic disease: a systematic review and meta-analysis","volume":"112","author":"Paixao","year":"2018","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2022.04.021_b0030","unstructured":"diseases, P. Available from: https:\/\/cepi.net\/research_dev\/priority-diseases\/. 2019."},{"key":"10.1016\/j.vaccine.2022.04.021_b0035","unstructured":"NIAID Emerging Infectious Diseases\/Pathogens. Available from: https:\/\/www.niaid.nih.gov\/research\/emerging-infectious-diseases-pathogens, Accessed on December 3, 2019."},{"key":"10.1016\/j.vaccine.2022.04.021_b0040","unstructured":"Diseases\/Pathogens, N.E.I. Available from: https:\/\/www.niaid.nih.gov\/research\/emerging-infectious-diseases-pathogens. 2019."},{"key":"10.1016\/j.vaccine.2022.04.021_b0045","unstructured":"WHO. Prioritizing diseases for research and development in emergency contexts; 2019."},{"key":"10.1016\/j.vaccine.2022.04.021_b0050","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.2147\/DDDT.S181574","article-title":"Recent development in the strategies projected for chikungunya vaccine in humans","volume":"12","author":"Goyal","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.vaccine.2022.04.021_b0055","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fimmu.2020.00592","article-title":"Current efforts in the development of vaccines for the prevention of Zika and Chikungunya virus infections","volume":"11","author":"Schrauf","year":"2020","journal-title":"Front Immunol"},{"issue":"50","key":"10.1016\/j.vaccine.2022.04.021_b0060","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2018.10.033","article-title":"Defining a correlate of protection for chikungunya virus vaccines","volume":"37","author":"Milligan","year":"2019","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.021_b0065","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1128\/JVI.06449-11","article-title":"Attenuation of chikungunya virus vaccine strain 181\/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein","volume":"86","author":"Gorchakov","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.04.021_b0070","unstructured":"BioSolutions, E., Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults; 2018"},{"issue":"36","key":"10.1016\/j.vaccine.2022.04.021_b0075","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.021_b0080","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.021_b0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ebiom.2017.03.006","article-title":"A rapid zika diagnostic assay to measure neutralizing antibodies in patients","volume":"17","author":"Shan","year":"2017","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.021_b0090","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.vaccine.2022.04.021_b0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.021_b0100","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.4049\/jimmunol.168.6.2880","article-title":"Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles","volume":"168","author":"Storni","year":"2002","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.021_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/v12010074","article-title":"Factors that govern the induction of long-lived antibody responses","volume":"12","author":"Chackerian","year":"2020","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.021_b0110","article-title":"Evaluation of DNA-launched virus-like particle vaccines in an immune competent mouse model of Chikungunya virus infection","volume":"9","author":"Rayner","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.04.021_b0115","article-title":"Co-immunization with CHIKV VLP and DNA vaccines induces a promising humoral response in mice","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.021_b0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002124","article-title":"Effective chikungunya virus-like particle vaccine produced in insect cells","volume":"7","author":"Metz","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"51","key":"10.1016\/j.vaccine.2022.04.021_b0125","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1016\/j.vaccine.2013.09.045","article-title":"Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits","volume":"31","author":"Metz","year":"2013","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.021_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108169","article-title":"Characterization of chikungunya virus-like particles","volume":"9","author":"Noranate","year":"2014","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.021_b0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004782","article-title":"Expression and characterization of yeast derived Chikungunya Virus Like Particles (CHIK-VLPs) and its evaluation as a potential vaccine candidate","volume":"10","author":"Saraswat","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.021_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007316","article-title":"Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice","volume":"13","author":"Arevalo","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.021_b0145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nm.2105","article-title":"A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection","volume":"16","author":"Akahata","year":"2010","journal-title":"Nat Med"},{"issue":"9959","key":"10.1016\/j.vaccine.2022.04.021_b0150","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/S0140-6736(14)61185-5","article-title":"Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial","volume":"384","author":"Chang","year":"2014","journal-title":"The Lancet"},{"issue":"52","key":"10.1016\/j.vaccine.2022.04.021_b0155","doi-asserted-by":"crossref","first-page":"13703","DOI":"10.1073\/pnas.1713166114","article-title":"Structural studies of Chikungunya virus maturation","volume":"114","author":"Yap","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.021_b0160","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/jvi.51.1.254-258.1984","article-title":"Structural proteins of Chikungunya virus","volume":"51","author":"Simizu","year":"1984","journal-title":"J Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.021_b0165","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.vaccine.2022.04.021_b0170","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00435","article-title":"Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization","volume":"2","author":"Sun","year":"2013","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.021_b0175","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.cell.2019.04.006","article-title":"Cryo-EM structure of Chikungunya Virus in Complex with the Mxra8 Receptor","volume":"177","author":"Basore","year":"2019","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.vaccine.2022.04.021_b0180","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2020.2477","article-title":"Effect of a Chikungunya virus-like particle vaccine on safety and tolerability outcomes: a randomized clinical trial","volume":"323","author":"Chen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2022.04.021_b0185","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jchromb.2016.04.025","article-title":"Characterization of N-glycosylation profiles from mammalian and insect cell derived chikungunya VLP","volume":"1032","author":"Lancaster","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.021_b0190","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nbt1095","article-title":"Baculovirus as versatile vectors for protein expression in insect and mammalian cells","volume":"23","author":"Kost","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.021_b0195","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.clim.2013.10.004","article-title":"Neutralizing monoclonal antibodies to the E2 protein of chikungunya virus protects against disease in a mouse model","volume":"149","author":"Goh","year":"2013","journal-title":"Clin Immunol"},{"issue":"13","key":"10.1016\/j.vaccine.2022.04.021_b0200","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1128\/JVI.01603-09","article-title":"Genome-scale phylogenetic analyses of chikungunya virus reveal independent emergences of recent epidemics and various evolutionary rates","volume":"84","author":"Volk","year":"2010","journal-title":"J Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.021_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030263","article-title":"Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak","volume":"3","author":"Schuffenecker","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2022.04.021_b0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijid.2017.03.006","article-title":"Global expansion of chikungunya virus: mapping the 64-year history","volume":"58","author":"Wahid","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"suppl 5","key":"10.1016\/j.vaccine.2022.04.021_b0215","doi-asserted-by":"crossref","first-page":"S441","DOI":"10.1093\/infdis\/jiw390","article-title":"Epidemiology of Chikungunya in the Americas","volume":"214","author":"Yactayo","year":"2016","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.021_b0220","doi-asserted-by":"crossref","first-page":"786","DOI":"10.4269\/ajtmh.1967.16.786","article-title":"Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues","volume":"16","author":"Harrison","year":"1967","journal-title":"Am J Trop Med Hyg"},{"issue":"15","key":"10.1016\/j.vaccine.2022.04.021_b0225","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/j.vaccine.2011.01.108","article-title":"A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2022.04.021_b0230","doi-asserted-by":"crossref","first-page":"8021","DOI":"10.1128\/JVI.02603-09","article-title":"Chikungunya virus arthritis in adult wild-type mice","volume":"84","author":"Gardner","year":"2010","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.021_b0235","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02449-17","article-title":"Chikungunya virus strains show lineage-specific variations in virulence and cross-protective ability in murine and nonhuman primate models","volume":"9","author":"Langsjoen","year":"2018","journal-title":"mBio"},{"issue":"16","key":"10.1016\/j.vaccine.2022.04.021_b0240","doi-asserted-by":"crossref","first-page":"8879","DOI":"10.1128\/JVI.00370-12","article-title":"A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design","volume":"86","author":"Akahata","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.021_b0245","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.virusres.2008.02.004","article-title":"Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates","volume":"135","author":"Santhosh","year":"2008","journal-title":"Virus Res"},{"key":"10.1016\/j.vaccine.2022.04.021_b0250","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.coviro.2016.02.007","article-title":"Interspecies transmission and chikungunya virus emergence","volume":"16","author":"Tsetsarkin","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.021_b0255","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.chom.2015.06.009","article-title":"Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus","volume":"18","author":"Smith","year":"2015","journal-title":"Cell Host Microbe"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.021_b0260","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/emmm.201200213","article-title":"Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein","volume":"4","author":"Kam","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"24","key":"10.1016\/j.vaccine.2022.04.021_b0265","doi-asserted-by":"crossref","first-page":"14364","DOI":"10.1128\/JVI.01943-14","article-title":"Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy","volume":"88","author":"Fong","year":"2014","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.021_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003312","article-title":"Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus","volume":"9","author":"Pal","year":"2013","journal-title":"PLoS Pathog"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.021_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002390","article-title":"Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants","volume":"7","author":"Lee","year":"2011","journal-title":"PLoS Pathog"},{"issue":"17","key":"10.1016\/j.vaccine.2022.04.021_b0280","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1128\/JVI.01286-14","article-title":"Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies","volume":"88","author":"Porta","year":"2014","journal-title":"J Virol"},{"issue":"23","key":"10.1016\/j.vaccine.2022.04.021_b0285","doi-asserted-by":"crossref","first-page":"13005","DOI":"10.1128\/JVI.01780-12","article-title":"Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development","volume":"86","author":"Kam","year":"2012","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.021_b0290","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/JVI.01918-10","article-title":"Host alternation of chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures","volume":"85","author":"Coffey","year":"2011","journal-title":"J Virol"},{"issue":"21","key":"10.1016\/j.vaccine.2022.04.021_b0295","doi-asserted-by":"crossref","first-page":"12233","DOI":"10.1128\/JVI.00247-14","article-title":"Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones","volume":"88","author":"Smith","year":"2014","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.021_b0300","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12964-020-00642-6","article-title":"A code within the genetic code: codon usage regulates co-translational protein folding","volume":"18","author":"Liu","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.021_b0305","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.3201\/eid1210.060610","article-title":"Novel chikungunya virus variant in travelers returning from Indian Ocean islands","volume":"12","author":"Parola","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.021_b0310","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/infdis\/jiw431","article-title":"A virus-like particle vaccine elicits broad neutralizing antibody responses in humans to all Chikungunya virus genotypes","volume":"214","author":"Goo","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.021_b0315","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/infdis\/jiz202","article-title":"Immunogenicity and efficacy of a measles virus-vectored Chikungunya vaccine in nonhuman primates","volume":"220","author":"Rossi","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.021_b0320","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jviromet.2019.04.013","article-title":"Development of a bead-based immunoassay using virus-like particles for detection of alphaviral humoral response","volume":"270","author":"Ricks","year":"2019","journal-title":"J Virol Methods"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.021_b0325","first-page":"599","article-title":"[Virus-like particle-based immunoglobulin M capture enzyme-linked immunosorbent assay for the detection of IgM antibodies against Chikungunya virus","volume":"30","author":"Li","year":"2014","journal-title":"Bing Du Xue Bao"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.021_b0330","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jmv.25420","article-title":"Detection of chikungunya virus-specific IgM on laser-cut paper-based device using pseudo-particles as capture antigen","volume":"91","author":"Theillet","year":"2019","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2022.04.021_b0335","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.virol.2019.01.027","article-title":"Comparative study of chikungunya Virus-Like Particles and Pseudotyped-Particles used for serological detection of specific immunoglobulin M","volume":"529","author":"Theillet","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2022.04.021_b0340","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.021_b0345","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00090-17","article-title":"Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus","volume":"24","author":"Urakami","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2022.04.021_b0350","unstructured":"Therapeutics V. To assess the safety, immunogenicity and efficacy of VLPM01 in Healthy, Malaria-Na\u00efve volunteers; 2019."},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.021_b0355","doi-asserted-by":"crossref","first-page":"218","DOI":"10.24875\/AIDSRev.19000114","article-title":"Designing chimeric virus-like particle-based vaccines for human papillomavirus and HIV: lessons learned","volume":"21","author":"Eto","year":"2019","journal-title":"AIDS Rev"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.021_b0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071047","article-title":"Characterization of synthetic Chikungunya viruses based on the consensus sequence of recent E1\u2013226V isolates","volume":"8","author":"Scholte","year":"2013","journal-title":"PLoS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T07:37:35Z","timestamp":1718437055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22004352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":72,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22004352"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunological implications of diverse production approaches for Chikungunya virus-like particle vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}